This year marks 110 years since CSL was founded with a simple purpose: to improve and protect human health. What began in 1916 as a small Australian laboratory has grown into a global biopharma company serving millions of people around the world. Over the past century, our purpose has remained constant. What drives us? Our commitment to patients and public health, our passion for scientific innovation and our determination to deliver high-quality medicines that save and improve lives. Today, CSL reaches millions of patients through world-class medicines across our five therapeutic areas – haematology, immunoglobulins, cardiovascular and renal, immunology and vaccines. For decades, our success has been built upon understanding patients’ needs, underpinned by excellent science, deep expertise and people who genuinely care about the patients and communities we serve. Each year, we measure our impact through facts and figures. While these numbers tell an important story, the people behind them matter most. Our medicines reached thousands of people living with rare diseases. Millions more relied on them at critical moments, whether welcoming a child or facing a medical emergency. As we look to the future, we remain focused on the purpose that has always guided CSL: delivering sustainable, improved outcomes for patients and public health. This report highlights the moments that mattered over the past year – for patients, for science and for society. Gordon Naylor Interim Chief Executive Officer & Managing Director From our CSL IMPACT REPORT 2026 | 7 | Introduction | For Patients | For Science | For Society | Looking Forward CEO
RkJQdWJsaXNoZXIy MjE2NDg3